SOPHiA GENETICS Announces Key Leadership Changes Leading Up to 2026 AGM

SOPHiA GENETICS Announces Key Leadership Transition Before 2026 AGM

SOPHiA GENETICS, a prominent player in Ai-driven precision medicine, has confirmed significant leadership changes ahead of its upcoming Annual General Meeting scheduled for June 18, 2026. This announcement highlights a strategic continuation of leadership to drive future growth and maintain operational excellence within the company.

New CEO Appointment

Effective July 1, 2026, Ross Muken will step into the role of Chief Executive Officer. Mr. Muken, who joined SOPHiA GENETICS in February 2021, has a wealth of experience that spans over 20 years in the life sciences and health technology sectors. He has held various executive positions, including Chief Financial Officer and Chief Operating Officer, before being named President in November 2024. His extensive knowledge of both financial operations and strategic development makes him a well-suited successor to steer the company forward.

Muken expressed his gratitude for the opportunity, stating, "I am deeply honored by Jurgi and the Board's confidence in me to lead SOPHiA GENETICS at this important moment. Jurgi has built a truly exceptional company with a clear mission, a differentiated platform, and a passionate team dedicated to improving patient outcomes."

Board Composition Changes

In addition to the CEO transition, the Board has nominated Dr. Jurgi Camblong, co-founder and current CEO, to serve as the Executive Chairman of the Board. Dr. Camblong has been at the helm since the company’s inception in 2011, guiding its evolution from a start-up into a publicly listed leader in the realm of precision medicine. Troy Cox, who has served as Chairman since March 2020, is up for re-election as a non-executive member of the Board, having overseen significant milestones such as the company's IPO on Nasdaq in 2021.

Strategic Importance of Leadership Changes

These appointments reflect a meticulously planned succession process that aims to ensure continuity in strategic leadership while also leveraging the Board’s experience. The proposal to nominate Dr. Camblong as the Executive Chairman enables him to continue playing an integral role in the company’s technology innovation and long-term strategy while allowing Muken to lead daily operations.

"Succession is one of the most important responsibilities of any board, and I am proud of the disciplined, multi-year process that has led to today’s announcement," Cox commented. He emphasized the unanimous support of the Board for this transition, stating, "The process has been rigorous, and the timing is right. I look forward to continuing to serve on the Board and to supporting Ross, Jurgi, and the entire team as they execute on the next chapter of SOPHiA GENETICS' mission."

Looking Ahead

With these changes in place, SOPHiA GENETICS is poised to leverage its innovative capabilities in Ai-powered precision medicine to enhance patient care and expand its global presence. Muken's commitment to building on the foundation that Dr. Camblong has established suggests a promising trajectory for the company as it continues to adapt and respond to the needs of the healthcare landscape.

Dr. Camblong expressed confidence in the transition, stating, "This transition marks an exciting new chapter, where I can strategically contribute at the Board level as we continue to advance our vision of democratizing data-driven medicine at scale."

As SOPHiA GENETICS approaches its Annual General Meeting, stakeholders will be keen to observe how the new leadership will impact the strategic direction and operations of this pioneering company.

About SOPHiA GENETICS

SOPHiA GENETICS is an Ai-native healthcare technology company dedicated to transforming patient care by expanding access to data-driven medicine worldwide. With its flagship platform, SOPHiA DDM™, the firm analyzes complex genomic and multimodal data, generating crucial insights for a growing network of healthcare institutions worldwide. For further information, visit SOPHiA GENETICS or connect on LinkedIn.